Structure Therapeutics enters three facility leases in Shanghai and South San Francisco

Structure Therapeutics Inc.

Operations lease for ~22,500 sq ft in Shanghai; annual rent ~5.20M yuan (~$0.72M); term Jan 2024–Dec 2026.
Lab lease for ~8,400 sq ft in Shanghai; annual rent ~1.99M–2.12M yuan (~$0.27–0.29M); term Feb 2024–Jan 2027.
Sublease for ~11,800 sq ft in South San Francisco; annual rent ~$0.49M initial +3% annual; term Aug 2023–Aug 2027, with 4-month rent abatement.
Leases support R&D operations in China and corporate headquarters in the US.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Structure Therapeutics Inc. entered into Sublease with Aligos Therapeutics, Inc. valued at approximately US$0.49 million (effective 2023-06-29).

Action: entry
Agreement: lease
Counterparty: Aligos Therapeutics, Inc.
Value: approximately US$0.49 million
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, Structure Therapeutics USA Inc., the Company’s wholly owned subsidiary (“Structure USA”) entered into a sublease agreement (the “Sublease”) with Aligos Therapeutics, Inc.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Structure Therapeutics Inc. entered into Lab Lease with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd. valued at approximately 1.99 million yuan, or approximately US$0.27 million (effective 2023-06-29).

Action: entry
Agreement: lease
Counterparty: Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.
Value: approximately 1.99 million yuan, or approximately US$0.27 million
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, Shanghai ShouTi, entered into a lease agreement (the “Lab Lease”) with Shanghai Chuangzhi Space Entrepreneurship Incubator Management Co., Ltd.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Structure Therapeutics Inc. entered into Operations Lease with Shanghai Changtai Business Management Co., Ltd. valued at approximately 5.20 million yuan, or approximately US$0.72 million (effective 2023-06-29).

Action: entry
Agreement: lease
Counterparty: Shanghai Changtai Business Management Co., Ltd.
Value: approximately 5.20 million yuan, or approximately US$0.72 million
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, Shanghai ShouTi Biotechnology Co., Ltd., the Company’s wholly owned subsidiary. (“Shanghai ShouTi”) entered into a lease agreement (the “Operations Lease”) with Shanghai Changtai Business Management Co., Ltd.

View on SEC.gov

Browse all material agreements →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-078719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.